



PATENT ATTORNEY DOCKET NO. 044574-5003-2

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re A	application of:	)	
	Subrahmanyam V. YERRAMILLI et al.	)	
Applic	eation No.: 10/004,427	) Group Art Unit: not yet assi	gned
Filed:	December 6, 2001	) Examiner: not yet assigned	
For:	A PROCESS TO STUDY CHANGES IN GENE EXPRESSION IN GRANULOCYTIC CELLS	) )	

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents are attached. Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

Michael S. Tuscan
Reg. No. 43,210

Dated: January 30, 2002 **Customer No. 09629** MORGAN, LEWIS & BOCKIUS LLP 1800 M Street, N.W. Washington, D.C. 20036-5869 (202) 739-3000

## INFORMATION DISCLOSURE SIVATION

Attorney Docket No. 044574-5003-2

Application No. 10/004,427

(Use several sheets if necessary)

Applicants: Subrahmanyam V. YERRAMILLI et al.

JAN 3 0 2002 PTO Form 1449

Filing Date: December 6, 2001

Group Art Unit: unassigned

IRAGE PATENTS DOCUMENTS						
*Examiner Initial	Document Number	Date	Name	Class	Sub Class	Filing Date
	5,650,299	7/22/97	Lawman et al.	435	70.7	10/6/94
	5,721,351	2/24/98	Levinson	536	23.4	6/7/95
		<u> </u>				

		FOREIC	GN PATENT DOCUMENTS				
	Document Number	Date	Country	Class	Sub Class	Transla YES	ntion NO
	WO 97/05286	02/13/97	PCT				
	WO 99/10538	03/04//99	PCT				
}							

 Moreb et al., 1997. "Human A1, a Bcl-2 Related Gene, is Induced in Leukemic Cells by Cytokines as Well Differentiating Factors." Leukemia. 11: 998-1004.					
Prashar et al., 1996. "Analysis of Differential Gene Expression by Display of 3' End Restriction Fragments of cDNAs." Proc. Natl. Acad. Sci. USA. 93: 659-663.					
Roberge, et al. 1996. "The IL-1 and IL-1 Receptor Antagonist (IL-1Ra) Response of Human Neutrophils to EBV Stimulation." Jour. Immun. 156: 4885-4891.					
Tagoh et al., 1996. "Molecular Cloning and Characterization of a Novel Stromal Cell-Derived cDNA Encodin a Protein That Facilities Gene Activation of Recombination Activating Gene (RAG)-1 in Human Lymphoid Progenitors." Biochemical and Biophysical Research Communications. 221: 744-749					
Tam et al., 1996. "Differential Expression of Macrophage Inflammatory Protein-2 and Monocyte Chemoattractant Protein-1 in Experimental Glomerulonephritis." Kidney International. 49: 715-721.					
Tam et al., 1994. "Glomerular Expression of Interleukin-1 Receptor Antagonist and Interleukin-1 $\beta$ Genes in Antibody-Mediated Glomerulonephritis." Amer. Jour. of Pathology, 145: 125-136.					

Examiner	Date Considered
Examiner:	on is in conformance with MPEP 609; draw line through citation if py of this form with next communication to applicant.